-
公开(公告)号：US08895031B2
公开(公告)日：2014-11-25
申请号：US12770638
申请日：2010-04-29
IPC分类号： A61K39/00 , A61K31/365
CPC分类号： G01N33/5023 , A61K31/365 , A61K39/0011 , A61K2039/5154 , G01N2333/90241 , G01N2500/10
摘要： The invention generally relates to the prevention and/or treatment of cancer, and, more specifically, to the treatment of tumors, including solid tumors and their metastases, without radiation or standard chemotherapeutic agents. In one embodiment, the invention involves a method comprising: a) providing a subject with tumor cells, b) removing at least a portion of said tumor cells from said subject to create removed cells, c) treating at least a portion of said removed cells ex vivo, using stimulating agents, including thapsigargin and/or thapsigargin-related compounds, so as to create treated tumor cells; and d) introducing said treated tumor cells (or fragments thereof) in vivo into the same subject to generate anticancer therapeutic effects.
摘要翻译： 本发明一般涉及癌症的预防和/或治疗，更具体地涉及治疗包括实体瘤及其转移瘤在内的肿瘤，无辐射或标准化学治疗剂。 在一个实施方案中，本发明涉及一种方法，其包括：a）向受试者提供肿瘤细胞，b）从所述受试者中除去至少一部分所述肿瘤细胞以产生去除的细胞，c）将至少一部分所述去除的细胞 离体使用刺激剂，包括毒胡萝卜素和/或毒胡萝卜素相关化合物，以产生经治疗的肿瘤细胞; 和d）将所述经处理的肿瘤细胞（或其片段）体内引入相同受试者以产生抗癌治疗效果。
-
2.发明授权Compositions and methods for suppression of amyloid plaque formation associated with neurodegenerative disorders 有权用于抑制与神经变性疾病相关的淀粉样斑块形成的组合物和方法公开(公告)号：US08329653B2
公开(公告)日：2012-12-11
申请号：US12296859
申请日：2007-04-16
CPC分类号： A61K38/18 , A61K9/0019 , A61K9/5123 , A61K47/542 , A61K47/549 , A61K47/64 , A61K47/6929
摘要： The invention provides methods and compositions for reducing or inhibiting net beta-amyloid peptide production and/or amyloid plaque formation. The methods and compositions involve administering a netrin-1 polypeptide or netrin-1 therapeutic to a subject in need thereof.
摘要翻译： 本发明提供用于减少或抑制净β-淀粉样蛋白肽产生和/或淀粉样蛋白斑形成的方法和组合物。 所述方法和组合物包括对有需要的受试者施用netrin-1多肽或netrin-1治疗剂。
-
3.发明申请CYTOTOXIC PEPTIDES AND PEPTIDOMIMETICS BASED THEREON, AND METHODS FOR USE THEREOF 审中-公开基于其的细胞毒素和基因组学及其使用方法公开(公告)号：US20110104715A1
公开(公告)日：2011-05-05
申请号：US12551400
申请日：2009-08-31
IPC分类号： G01N33/68
CPC分类号： C07K14/4747 , A61K38/00 , C07K14/4711
摘要： In accordance with the present invention, it has been discovered that the β-amyloid precursor protein (APP), and two APP-like proteins (APLP1 and APLP2) are proteolytically cleaved by caspases in the C terminus to generate an approximately 31 amino acid peptide. It has been further discovered that the resultant C-terminal peptide is a potent inducer of apoptosis. Both caspase-cleaved APP and activated caspase-9 is present in brains of Alzheimer's disease patients but not in control brains. These findings indicate that caspase cleavage of APP and APP-like proteins leads to the generation of apoptotic peptides, which may contribute to the neuronal death associated with Alzheimer's disease. Accordingly, there are provided compositions and methods for modulating apoptosis.
摘要翻译： 根据本发明，已经发现，C端的半胱氨酸蛋白酶蛋白水解切割β-淀粉样蛋白前体蛋白（APP）和两种APP样蛋白（APLP1和APLP2），以产生约31个氨基酸 肽。 进一步发现所得的C末端肽是细胞凋亡的有效诱导剂。 半胱氨酸蛋白酶切割的APP和活化的半胱天冬酶-9均存在于阿尔茨海默病患者的脑中，但不存在于对照脑中。 这些发现表明，APP和APP样蛋白的半胱天冬酶切割导致凋亡肽的产生，这可能有助于与阿尔茨海默氏病相关的神经元死亡。 因此，提供了调节凋亡的组合物和方法。
-
公开(公告)号：US20090041745A1
公开(公告)日：2009-02-12
申请号：US12167912
申请日：2008-07-03
申请人： Sabina SPERANDIO , Dale E. Bredesen
发明人： Sabina SPERANDIO , Dale E. Bredesen
CPC分类号： G01N33/5011 , A61K31/198 , A61K31/40 , A61K31/42 , A61K31/421 , A61K31/47 , A61K31/473 , A61K31/739 , A61K38/046 , A61K38/1709 , A61K38/191 , A61K38/4873 , A61K45/06 , G01N33/5008 , G01N33/5017 , G01N2510/00
摘要： The invention is directed to a method of modulating paraptotic cell death in a cell by contacting the cell with an effective amount of a compound selected from the group consisting of ceramide, Tumor Necrosis Factor (TNF), caspase-7, caspase-8, α-amino-3-hydroxy-5-methyl-4-isoxazole proprionic acid (AMPA), kainic acid and glutamic acid, wherein the effective amount of the compound induces paraptotic death of the cell. The invention further is directed to a method of inhibiting paraptotic cell death in a cell by contacting the cell with an effective amount of a compound selected from the group consisting of Alg-2-interacting protein 1 (AIP-1), Jun N-terminal kinase 1 (JNK1) neutralizing agent, Jun N-terminal kinase 2 (JNK2) neutralizing agent, TNF Receptor-Associated Factor 2 (TRAF2) neutralizing agent, ortho-phenanthroline and the JNK inhibitor SP 600125, wherein the effective amount of the compound inhibits paraptotic death of the cell.
摘要翻译： 本发明涉及一种通过使细胞与有效量的选自神经酰胺，肿瘤坏死因子（TNF），半胱天冬酶-7，半胱天冬酶-8，阿尔茨海默氏症的化合物接触来调节细胞中paraptotic细胞死亡的方法 - 氨基-3-羟基-5-甲基-4-异恶唑丙酸（AMPA），红藻氨酸和谷氨酸，其中该化合物的有效量诱导细胞的副作用死亡。 本发明还涉及通过使细胞与有效量的选自由Alg-2相互作用的蛋白1（AIP-1），Jun N末端组成的组中的化合物接触来抑制细胞中的旁分泌细胞死亡的方法 激酶1（JNK1）中和剂，JunN-末端激酶2（JNK2）中和剂，TNF受体相关因子2（TRAF2）中和剂，邻菲咯啉和JNK抑制剂SP600125，其中该化合物的有效量抑制 细胞的paraptotic死亡。
-
公开(公告)号：US06235872B1
公开(公告)日：2001-05-22
申请号：US09041886
申请日：1998-03-12
IPC分类号： C07K700
CPC分类号： C07K7/08 , A61K38/00 , A61K48/00 , C07K14/4747
摘要： The present invention provides substantially pure proapoptotic dependence peptides. The peptides consist substantially of the sequence of an active dependence domain selected from the group of dependence polypeptides consisting of p75NTR, androgen receptor, DCC, huntingtin polypeptide, Machado-Joseph disease gene product, SCA1, SCA2, SCA6 and atrophin-1 polypeptide. Substantially pure proapoptotic dependence peptides include SATLDALLAALRRI (SEQ ID NO:3), Q14 (SEQ ID NO:7), SATLDALLAALGGI (SEQ ID NO:4), SATLDALLAALRGI (SEQ ID NO:5), SATLQALLAALRRI (SEQ ID NO:6), tat-GG-SATLDALLAALRRI (SEQ ID NO:37) and tat-GG-Q14 (SEQ ID NO:36).
摘要翻译： 本发明提供基本上纯的促凋亡依赖性肽。 所述肽基本上由选自由p75NTR，雄激素受体，DCC，亨廷顿肽多肽，马查多 - 约瑟夫病基因产物，SCA1，SCA2，SCA6和萎缩蛋白-1多肽组成的依赖性多肽组的活性依赖结构域的序列组成。 基本上纯的促凋亡依赖肽包括SATLDALLAALRRI（SEQ ID NO：3），Q14（SEQ ID NO：7），SATLDALLAALGGI（SEQ ID NO：4），SATLDALLAALRGI（SEQ ID NO：5），SATLQALLAALRRI（SEQ ID NO：6） ，tat-GG-SATLDALLAALRRI（SEQ ID NO：37）和tat-GG-Q14（SEQ ID NO：36）。
-
公开(公告)号：US06231852B1
公开(公告)日：2001-05-15
申请号：US08707055
申请日：1996-09-03
申请人： Dale E. Bredesen
发明人： Dale E. Bredesen
IPC分类号： A61K3844
CPC分类号： C12N5/00 , A61K31/05 , A61K31/06 , A61K31/085 , A61K31/16 , A61K31/444 , C12N2501/48 , C12N2510/00 , Y10S514/885
摘要： Methods for controlling cell death when the cell is exposed to one or more potentially lethal cellular insults. In one method, cell death is inhibited by introducing a reactive oxygen species limiter into the cell which prevents the build up of lethal levels of reactive oxygen species when the cell is exposed to a cellular insult. In another method, cell death is promoted in cancer cells or other proliferating cells which are naturally resistant to lethal cellular insults. The method involves neutralizing reactive oxygen species limiters, such as bcl-2, which occur naturally in cancer cells and which prevent the build up of reactive oxygen species within the cancer cells when they are exposed to lethal cellular insult. Neutralizing the reactive oxygen species limiter leaves the cancer cell unable to protect itself when cellular insult causes increases in the level of reactive oxygen species. The result is an increase in cell death.
摘要翻译： 当细胞暴露于一种或多种潜在的致死细胞损伤时控制细胞死亡的方法。 在一种方法中，通过在细胞中引入活性氧限制剂来抑制细胞死亡，当细胞暴露于细胞损伤时，其可防止致死水平的活性氧的形成。 在另一种方法中，细胞死亡在癌细胞或天然抗致死细胞损伤的其他增殖细胞中被促进。 该方法包括中和活性氧限制因子，例如bcl-2，其在癌细胞中天然存在，并且当它们暴露于致死细胞损伤时，其防止癌细胞内的活性氧物质的积聚。 中和活性氧限制器使癌细胞无法保护自身，当细胞损伤引起活性氧物质水平升高时。 结果是细胞死亡的增加。
-
公开(公告)号：US10449177B2
公开(公告)日：2019-10-22
申请号：US13213960
申请日：2011-08-19
申请人： Varghese John , Dale E. Bredesen
发明人： Varghese John , Dale E. Bredesen
IPC分类号： A61K31/4035 , A61K31/05 , A61K31/145 , A61K31/5513
摘要： The invention provides compositions and methods for the treatment of mild cognitive impairment (MCI), and for inhibiting, reducing, delaying and/or preventing the progression of MCI to Alzheimer's disease. The methods entail administering an effective amount of one or more compounds selected from the group consisting of tropisetron, disulfuram, honokiol and nimetazepam. The methods also are useful for prophylactic and therapeutic treatment of amyloidogenic diseases, including Alzheimer's disease.
-
8.发明申请METHODS OF TREATING MILD COGNITIVE IMPAIRMENT (MCI) AND RELATED DISORDERS 审中-公开治疗MILD认知障碍（MCI）和相关疾病的方法公开(公告)号：US20120071468A1
公开(公告)日：2012-03-22
申请号：US13213960
申请日：2011-08-19
申请人： Varghese John , Dale E. Bredesen
发明人： Varghese John , Dale E. Bredesen
CPC分类号： A61K31/4035 , A61K31/05 , A61K31/145 , A61K31/5513
摘要： The invention provides compositions and methods for the treatment of mild cognitive impairment (MCI), and for inhibiting, reducing, delaying and/or preventing the progression of MCI to Alzheimer's disease. The methods entail administering an effective amount of one or more compounds selected from the group consisting of tropisetron, disulfuram, honokiol and nimetazepam. The methods also are useful for prophylactic and therapeutic treatment of amyloidogenic diseases, including Alzheimer's disease.
摘要翻译： 本发明提供了用于治疗轻度认知障碍（MCI）以及用于抑制，减少，延迟和/或预防MCI进展为阿尔茨海默病的组合物和方法。 所述方法需要施用有效量的一种或多种选自托烷司琼，二硫酚，和厚朴酚和尼米西泮的化合物。 所述方法还可用于预防和治疗淀粉样变性疾病，包括阿尔茨海默氏病。
-
公开(公告)号：US20100278874A1
公开(公告)日：2010-11-04
申请号：US12770638
申请日：2010-04-29
IPC分类号： A61K39/00 , A61K31/343 , A61P35/00
CPC分类号： G01N33/5023 , A61K31/365 , A61K39/0011 , A61K2039/5154 , G01N2333/90241 , G01N2500/10
摘要： The invention generally relates to the prevention and/or treatment of cancer, and, more specifically, to the treatment of tumors, including solid tumors and their metastases, without radiation or standard chemotherapeutic agents. In one embodiment, the invention involves a method comprising: a) providing a subject with tumor cells, b) removing at least a portion of said tumor cells from said subject to create removed cells, c) treating at least a portion of said removed cells ex vivo, using stimulating agents, including thapsigargin and/or thapsigargin-related compounds, so as to create treated tumor cells; and d) introducing said treated tumor cells (or fragments thereof) in vivo into the same subject to generate anticancer therapeutic effects.
摘要翻译： 本发明一般涉及癌症的预防和/或治疗，更具体地涉及治疗包括实体瘤及其转移瘤在内的肿瘤，无辐射或标准化学治疗剂。 在一个实施方案中，本发明涉及一种方法，其包括：a）向受试者提供肿瘤细胞，b）从所述受试者中除去至少一部分所述肿瘤细胞以产生去除的细胞，c）将至少一部分所述去除的细胞 离体使用刺激剂，包括毒胡萝卜素和/或毒胡萝卜素相关化合物，以产生经治疗的肿瘤细胞; 和d）将所述经处理的肿瘤细胞（或其片段）体内引入相同受试者以产生抗癌治疗效果。
-
公开(公告)号：US20100099609A1
公开(公告)日：2010-04-22
申请号：US12510831
申请日：2009-07-28
CPC分类号： A61K38/1716 , A61K47/58 , A61K47/59 , A61K47/60 , A61K47/61
摘要： This invention provides methods of reducing levels of amyloid beta (Aβ) protein and/or netrin-1 in a mammal. In certain embodiments the methods involve administering to the mammal a fragment of an amyloid precursor protein, or a mutant amyloid precursor protein, in an amount sufficient to decrease circulating levels of free Aβ protein in said mammal, wherein said fragment is a fragment of the extracellular domain of APP or a mutant thereof that binds amyloid beta protein and/or netrin-1.
摘要翻译： 本发明提供降低哺乳动物中淀粉样蛋白β（A＆bgr））蛋白和/或netrin-1水平的方法。 在某些实施方案中，所述方法包括给予哺乳动物淀粉样蛋白前体蛋白片段或突变型淀粉样蛋白前体蛋白，其量足以降低游离A和Bgr的循环水平; 蛋白质，其中所述片段是APP的细胞外结构域的片段或其结合淀粉样蛋白β蛋白和/或netrin-1的突变体。
-
-
-
-
-
-
-
-
-
搜索结果
29 条记录 (耗时 0.026 秒)
